Effect of Novel Biotherapeutic Elevating Angiopoietin 1 on Progression of Diabetic Nephropathy in Diabetic/Obese Mice


Cardiometabolic Diseases Research (CB, PS, MM, VB, SK, HQ, MM, HC, AZ, MC, HR, RF), Biotherapeutic Discovery (CZ, JM), Biotherapeutic Pharmacokinetics (TB, JG), Target Discovery Research (TL)

Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA 06877

*shared first-authorship
Elevated ANGPT1 Protects Diabetic Nephropathy

Corresponding Author:

Ryan M. Fryer, Ph.D.
Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
Ridgefield CT 06877-0368
ryan.fryer@boehringer-ingelheim.com
(203) 778-7928 (phone)
(203) 837-5938 (fax)

Text pages: 22
Figures: 6 + 1 Supplemental Figure
References: 24
Abstract: 249/250 words
Introduction: 603/750 words
Discussion: 984/1500 words
Nonstandard Abbreviations (alphabetical order): AAV, Adeno-associated virus; ANGPT1, angiopoietin 1; ANGPT2, angiopoietin 2; CKD, chronic kidney disease; COMP-Ang1, chimeric protein of cartilage oligomeric matrix protein and angiopoietin 1; DN, diabetic nephropathy; ESRD, end stage renal disease; HUVEC, Human umbilical vein endothelial cells; MoA, mechanism-of-action; TIE2: Tyrosine Kinase with Ig And EGF Homology Domains-2; TNFα, Tumor necrosis factor alpha; VG, vector genomes, RT, resting tension, PE, phenylephrine

Recommended section assignment: Drug Discovery and Translational Medicine
Abstract

Diabetic nephropathy is a leading cause of ESRD, characterized by endothelial dysfunction and compromised glomerular permeability barrier. Dysregulation of the ANGPT1/ANGPT2 signaling axis is implicated in disease progression. We recently described the discovery of an IgG1 antibody, O010, with therapeutic potential to elevate circulating endogenous ANGPT1, a TIE2 agonist. Studies are described that detail the effect of various ANGPT1 elevating strategies to limit progression of renal dysfunction in diabetic-obese (db/db) mice. Results demonstrate that AAV- or DNA minicircle-directed overexpression of ANGPT1 elicits a reduction in albuminuria (56-73%) and an improvement in histopathology score (18% reduction in glomerulosclerosis). An improved acetylcholine response in isolated aortic rings was also observed indicative of a benefit on vascular function. In separate pharmacokinetic studies an efficacious dose of the ANGPT1 DNA minicircle increased circulating levels of the protein by >80% resulting in a concomitant suppression of ANGPT2. At a dose of O010 producing maximal elevation of circulating ANGPT1 achievable with the molecule (60% increase), no suppression of ANGPT2 was observed in db/db suggesting insufficient pathway engagement; no reduction in albuminuria or improvement in histopathological outcomes were observed. To pinpoint the mechanism resulting in lack of efficacy we demonstrate using confocal microscopy an interference with TIE2 translocation to adherens junctions resulting in a loss of protection against vascular permeability normally conferred by ANGPT1. Results demonstrate the essential importance of ANGPT1 to maintain the glomerular permeability barrier, and due to interference of O010 with this process, led to the discontinuation of the molecule for clinical development.
Significance Statement

This body of original research demonstrates that elevation of systemic angiopoietin 1 is protective against diabetic nephropathy. However, using a novel biotherapeutic approach to elevate systemic ANGPT1 renoprotection was not observed; we demonstrate that protection was lost due to interference of the therapeutic with ANGPT1/TIE2 translocation to adherens junctions. Thus, the clinical development of the antibody was terminated.
Introduction

In a pivotal paper using untargeted proteomic profiling of circulating proteins from patients with diabetes, the “Joslin Kidney Study”, elevated plasma ANGPT1 was associated with protection against progressive renal decline and progression of end stage renal disease (Dom et al., 2021). Angiopoietin-1 (ANGPT1) is a 70 kD glycoprotein and the major agonist for the tyrosine kinase receptor, Tek (also termed TIE2), expressed primarily on endothelial cells including glomerular endothelial cells (Davis et al., 1996; Satchell et al., 2002). ANGPT1 is required to maintain endothelial cell quiescence, promote restoration of vascular function, and regulate vascular permeability (Uemura et al., 2002). In contrast, Angiopoietin-2 (ANGPT2), released from Weibel-Palade bodies (Fiedler et al., 2004), is a functional antagonist of ANGPT1-binding to TIE2, thereby inhibiting TIE2 signaling and thus promotes endothelial activation, destabilization, and vascular leakage (Fiedler and Augustin, 2006).

In diabetic nephropathy (DN), a leading cause of end-stage renal disease worldwide (Bell et al., 2015; Ghaderian et al., 2015), it has been suggested that there is dysregulation of the ANGPT1-ANGPT2-TIE2 axis in disease, both in humans and in pre-clinical models. Circulating ANGPT1 is decreased whereas ANGPT2 is elevated in chronic kidney disease (CKD) patients with moderately to severely reduced glomerular filtration rate (Futtrakul et al., 2008). Intriguingly, ANGPT2 expression is negatively regulated via an ANGPT1-TIE2 downstream signaling pathway through AKT and FOXO1 in human endothelial cells (Daly et al., 2004). Thus, reduced ANGPT1 in disease may be permissive for ANGPT2 synthesis, further exacerbating endothelial dysfunction in CKD. Similarly, in animal models of kidney disease, ANGPT1 is reduced and correlated with increased glomerulosclerosis and albuminuria (Yuan et al., 2002; Jeansson et al., 2011) suggesting a conserved disease etiology in rodents.
ANGPT1 may be especially important in the context of maintaining renal function given its predominate cortical expression in podocytes and juxtaposition to glomerular endothelia. Exquisite studies in healthy adult podocytes using high-power multiplexed immunofluorescence analyses in combination with immunohistochemical analyses demonstrate clear podocyte ANGPT1 expression in the foot process, co-localized with nephrin, whereas Tie2 is predominately expressed in the glomerular endothelium particularly on the abluminal surface (Satchell et al., 2002). The cellular localization of these proteins lends to the stabilization of the glomerular capillary structure (to reduce permeability), especially at adherens junctions, and thus limit protein leak into the urine under normal conditions. Indeed, in diabetic mice podocyte-specific deletion of ANGPT1 exacerbates glomerular damage and precipitates proteinuria (Jeansson et al., 2011).

Thus, enhancing ANGPT1-TIE2 signaling to restore endothelial function in CKD may offer promising therapeutic potential to reverse the course of disease. Unfortunately, the magnitude increases in circulating ANGPT1 necessary to stimulate glomerular endothelial TIE2, and reverse the pathology, is unclear. This is compounded by the difficulty to accurately measure ANGPT1 in circulation due to ex vivo activation of platelets that may have artificially confounded values reported in previous clinical studies (Reed and Schrier, 2011).

Previously, we reported the discovery of a novel IgG1-based molecule that selectively increases circulating ANGPT1 by binding to, and stabilizing, ANGPT1 at an epitope outside the TIE2 binding domain. We also demonstrated proof of concept that the same molecule, termed O010, significantly elevates circulating levels of the protein in cynomolgus monkeys after a single injection of the antibody (Zheng et al., 2018).

Building on these observations, in this body of work we utilize different strategies to overexpress ANGPT1 in the circulation and test the impact of elevated ANGPT1 protein on progression to kidney
disease in mice. Furthermore, we define the necessary circulating ANGPT1 levels that successfully restored renal and vascular function and tested the effect of the ANGPT1-elevating antibody, O010, for proof of concept to reduce renal dysfunction and support advancement into clinical development.
Materials and Methods

Materials (antibody, DNA Minicircle, AAV): Mouse ANGPT1 minicircle was obtained from System Biosciences (Palo Alto, CA). The ANGPT1 antibody O010, and the IgG control antibody were produced at Boehringer Ingelheim Pharmaceuticals as previously disclosed (Zheng et al., 2018). The COMP-Ang1 AAV (Cho et al., 2004) was produced as follows: a synthetic piece of DNA containing a Kozak sequence followed by a secretory signal sequence for hemagglutinin, the coiled-coil domain of rat cartilage oligomeric matrix protein fused to the fibrinogen-like domain of human Ang1 (Cho et al., 2004) and a WPRE sequence was synthesized at GeneArt (Regensburg, Germany) and cloned into the pAAV-MCS (Agilent Technologies, catalog no. 240071) without ß-globin intron (Aschauer et al., 2003) via the ClaI and BglII restriction sites and termed pAAV_CMV-COMP-Ang1. The pAAV-Stuffer (Strobel et al., 2015) was used as a control. A commercially available packaging plasmid consisting of AAV2 rep, AAV8 cap, and Ad5 helper function (PlasmidFactory, catalog no. pDPape8) was used for packaging the rAAV constructs containing AAV2-ITRs into an AAV8 capsid. The rAAV8 vectors were produced as described previously (Aschauer et al., 2003).

Measurement of ANGPT1 and ANPGT2 in plasma: ANGPT2 plasma concentrations were measured using Mouse/Rat quantikine ELISA kits (R&D Systems) per the manufacturer's instructions. ANGPT1 plasma concentrations were measured using an MSD (Meso Scale Discovery) assay. Briefly, gold small spot streptavidin plates (MSD part #L45SA) were coated with 1 µg/mL biotinylated mouse monoclonal anti-human Ang1 antibodies (R&D Systems, MAB9231), then incubated overnight at 2-8°C. The plates were washed (1X PBS with 0.05% Tween 20) then blocked with 5% BSA (SeraCare) containing 0.05% Tween 20. Following incubation for 1 hour at ambient temperature, plates were washed and reference standard (recombinant mouse ANGPT1 protein, R&D Systems) and test samples diluted 2x in MSD diluent 7 were added for 2 hours at ambient temperature. The plates were washed and MSD Sulfo-labeled polyclonal
goat anti-human Ang1 (R&D Systems, AF923) diluted to 1 µg/mL with MSD diluent 3 was added and incubated for 2 hours at ambient temperature. After washing, 2x MSD Read Buffer was added and the electrochemiluminescence (ECL) signal was then measured on a Sector Imager 6000 instrument. Analyte concentrations were determined from data regression of the ECL signal converted to concentration values. Quantitation was based on a four-parameter logistic \((1/Y^2)\) regression equation from reference standard curves generated using the MSD Discovery Workbench software.

**Western Blot:** Kidney cortex from mice were homogenized using IP Lysis Buffer containing Halt Protease and Phosphatase Inhibitors with Lysing Matrix D tubes on a MP Fastprep-24 5G Instrument. Protein (BCA) quantification was determined and samples were normalized to 1 mg/mL for immunoprecipitation overnight rotating at 4°C with 4 μg of mouse/rat Tie-2 Antibody (R&D Systems AF762). 50 μg of protein was used for polyacrylamide gel electrophoresis, transferred to 0.45 μm nitrocellulose membranes, and incubated with 5% skim milk before incubating with antibodies.

The anti-TIE2 (phospho Y1102) antibody ab111585 (1:50) was used to detect phosphorylation; mouse/rat Tie-2 antibody (R&D Systems AF762, 0.1 µg/mL) was used for total TIE2 immunoprecipitation and IgG heavy chain as a loading control.

The membrane was washed three times with Tris buffered saline with Tween20 (TBST) and incubated with secondary antibodies (1:5000 dilution) at room temperature for 1 hr. The membranes were washed again and chemiluminescence (ECL) detection was carried out.

**In vivo Pharmacology:** All in vivo experiments were conducted in compliance with the rules set forth by the Boehringer Ingelheim Institutional Animal Use and Care Committee (IACUC) in accordance with the guidelines established in the National Institutes of Health, Guide for the Care and Use of Laboratory Animals. Studies were conducted in Boehringer Ingelheim’s AAALAC (International, Association for the Assessment and Accreditation of Laboratory Animal Care) accredited facility.
Male db/db mice and their controls, db/m mice, were purchased from Charles River Laboratories (Kingston, NY) at 7–8 weeks of age with or without uninephrectomy performed at 5 weeks of age, as detailed in the results. Mice were acclimated for 3 days upon arrival and were housed in groups of 2-3/cage with a twelve-hour light-dark cycle and ad libitum access to food and water. All in vivo studies were designed in a similar fashion; any notable differences are described in the results. In brief, mice were randomly assigned to treatment groups based on average baseline urinary albumin excretion (UAE) and body weight. Mice were single housed in metabolic cages for urine collection; blood samples were collected from the jugular vein (interim timepoint) or cardiac puncture (terminal timepoint) for purposes of measuring soluble factors or antibody PK. At study termination, mice were sacrificed by exsanguination through cardiac puncture under isoflurane anesthesia, and tissues were collected for ex vivo, histologic, or other relevant analysis as detailed in the results section.

**Histology:**

*Tissue Collection and Processing:* For histologic assessment, kidneys were removed and weighed, and a mid-organ transverse section of the left kidney was collected and immediately fixed by immersion in 10% phosphate-buffered formalin for 48 hours. Subsequently, formalin-fixed tissues were washed in phosphate buffer, dehydrated through a graded series of ethanol and xylene, embedded in paraffin, and sectioned at 4 µm.

*General Assessment of Renal Histopathology:* Kidney tissue sections (4 µm) were stained with periodic acid methenamine silver for the general assessment of incidence of glomerulosclerosis and H&E for the general assessment of total number of foci of interstitial lesions. For the glomerular lesions, the number of glomeruli showing mild to severe glomerulosclerosis was counted in each kidney section and expressed as a percentage of the total glomerular population. Tubulointerstitial lesions were assessed as the number of foci showing obvious renal damage, which included marked hypercellularity.
(inflammation or resident myofibroblast increases), fibrosis, tubular hyperplasia, casts, or necrosis. Both assessments were performed under blinded conditions at 10x magnification.

**Immunohistochemistry and quantification of glomerular podocytes:** 4 µm kidney sections were air dried overnight at 37°C, dewaxed, and rehydrated in graded ethanol to phosphate-buffered saline. Endogenous peroxidase activity was blocked by ImmPRESS (Vector Laboratories, Burlingame, CA) for 20 minutes at ambient temperature. Sections were then washed and incubated with the primary antibody for p57 (tissue marker of glomerular podocyte, sc8298; Santa Cruz, Dallas, TX) at a dilution of 1:500 and were subsequently incubated with the respective secondary antibodies (ImmPress Reagent Kit; Vector Laboratories, Burlingame, CA) for 30 minutes in a hydration chamber. Immunoperoxidase detection was performed using the avidin-biotin complex method (Vector Laboratories) using 3,3'-diaminobenzidine tetrahydrochloride as substrate. Quantification of glomerular podocyte was performed under blinded conditions. Thirty random digital images were captured at 20x objective magnification, and the number of podocyte or the cell number with positive expressed p57 for each individual glomeruli was counted manually for all thirty images and the final result was calculated as average number of podocyte per glomeruli.

**Aortic Ring:** Aortic rings from mouse aortas of ~2 mm in length were cleaned of adherent connective tissue, isolated, and immediately transferred into a chilled (4 °C) Krebs’ solution composed of: CaCl₂ (anhydrous) 0.28g; NaHCO₃, 2.1g; HEPES, 1M and Kreb’s powder (Kreb’s-Henseleit Buffer modified, K3753-10x1L). Kreb’s was previously bubbled with a mix of gases contained 95% O₂ + 5% CO₂ to pH 7.4. Aortic rings were mounted into a wire myograph system. Each ring was placed on two wire hooks in block-heated tissue baths containing 8 mL of the same Krebs’ solution kept at 37 °C and constantly bubbled with 95% O₂ + 5% CO₂. The upper hook was connected to a force transducer to detect changes in isometric force; changes in isometric force were continuously recorded using Chart 5.4 (PowerLab, AD Instruments Inc., North America). Passive tension was set to 1.55 g and all subsequent measurements
representing the force were generated above this baseline. A 1 hr equilibration period was applied before any experimental intervention, during which the bath was flushed with fresh Krebs’ solution every 30 min. After equilibration, the aortic rings were tested with a single dose of KCl (50 mM) to confirm smooth muscle viability. After maximal contraction was reached, the tissue baths were washed with fresh Krebs solution 3 times and left to re-equilibrate for another 20 minutes. Following relaxation back to baseline, the tissues were pre-constricted with phenylephrine (PE) at a concentration of 10^{-6} M. The vessels were allowed to constrict to the maximum response to PE then a cumulative dose response curve with acetylcholine was performed at the following concentrations: 10^{-9}, 3\times 10^{-9}, 10^{-8}, 3\times 10^{-8}, 10^{-7}, 3\times 10^{-7}, 1\times 10^{-6}, 3\times 10^{-6}, 1\times 10^{-5} M. Analysis of the EC_{50} for each dose response curve was performed and the EC_{50} determined using GraphPad Prism 9 software (data transformed into logarithmic scale values (X=1e-9*X) and then X=log(X)) and the EC_{50} determined using nonlinear regression (curve fit) dose-response inhibition (Log(inhibitor) vs. response-Variable slope (four parameters) (Formula Y=Bottom + (Top-Bottom)/(1+10^{((LogIC50-X)*HillSlope)}).

**Phospho-TIE2 localization:** Pooled donor HUVECs (Lonza, CC-2519A) were cultured in EGM-2 media according to manufacturer instructions. To determine the effect of ANGPT1 non-neutralizing antibody on pTIE2 localization, passage 3 HUVECs were plated on collagen I-coated chamber slides (Corning, 354630) at a density of 30,000 cells per well. Cells were switched into starvation media 4 hours post plating. The following morning, HUVECs were stimulated with starvation media containing 500 ng/mL recombinant human ANGPT1 (BIPI ID PW.PR.00346095, lot FHW381501A) with or without 100 nM non-neutralizing ANGPT1 antibody (0010, BIPI ID PW.PR.00349790, lot dliu3_20161018_090.3CEX) for 30 minutes at 37°C. Media was aspirated and cells were fixed with 4% paraformaldehyde for 15 minutes at 4°C. Cells were washed in phosphate-buffered saline, permeabilized with 0.05% TritonX-100, and washed again prior to blockade in 1% BSA, 10% donkey serum in phosphate-buffered saline. Slides were
incubated in primary antibodies for phospho-TIE2 (Y992; R&D Systems, AF2720, 1:25) and VE-cadherin (R&D Systems, MAB9381, 1:500) overnight in blocking solution at 4°C. The following day, slides were washed in PBS and incubated in secondary antibodies (anti-rabbit Alexa488, anti-mouse Alexa594; Invitrogen) in blocking solution for 60 minutes at room temperature in the dark, stained with DAPI and mounted with SlowFade Diamond (ThermoFisher, S36967). Slides were imaged using 20x magnification on a LSM 880, AxioObserver Zeiss confocal microscope.

Images were processed using Fiji-ImageJ. To quantify the junctional pTIE2, the VE-cadherin channel was converted to a binary image for generation of a mask which was overlaid onto the pTIE2 image allowing for quantification of pTIE2 signal localized within the adherens junctions. The area, mean density and integrated densities were captured from each well. Each experiment contained 3-9 well replicates and two independent experiments were performed.

**Permeability assay:** Pooled donor HUVECs (Lonza, CC-2519A) were cultured in EGM-2 media and evaluated using the In Vitro Vascular Permeability Assay following manufacturer instructions (96-well; Millipore, ECM642). Briefly, 50000 HUVECs were seeded onto a pre-hydrated collagen I-coated inserts in 100 uL of EGM-2 media and the receiver filled with 250 uL EGM-2. Cells were incubated for 48 hours prior to stimulation with vascular permeability factors (10 ng/mL TNF alpha (EMDMillipore, GF442), 200 ng/mL ANGPT1, and 100 nM O010 or IgG1 control antibody). After 24 hrs, media containing permeability factors was removed and 75 uL of a 1:40 FITC-Dextran solution in EGM-2 was added to the insert and placed in 250 uL of EGM-2 in the receiver tray. Permeation continued for 20 min after which the inserts were removed, media in the receiver tray was mixed by pipetting, and 100 uL was transferred to a black walled opaque plate. Fluorescence was measured on a SpectraMax 5 with 485 nm excitation and 535 nm emission filters, using 4 replicates per group per experiment. Two independent experiments were performed, and the data are presented as the relative fluorescence units in the receiver well ± SEM from one experiment.
**Statistical Analysis:** As appropriate, experimental results are shown both as individual data points and mean ± SEM. Since more than one statistical method was used based on the experimental conditions or comparator groups, the specific statistical test performed is detailed within the results for each experiment or set of data.
Results

Effect of ANGPT1 overexpression using COMP-Ang1 AAV on DN progression in db/db mice (Figure 1):

The ANGPT1 variant, COMP-Ang1, has been previously characterized as an ANGPT1-like TIE2 agonist to promote receptor signaling in vivo (Kim et al., 2008; Ryu et al., 2015). In the present study COMP-Ang1 AAV was delivered via tail vein injection to db/db mice at 1x10^10 VG/mouse and mice were euthanized 8 weeks post injection. COMP-Ang1 injection resulted in a 51.2% increase in renal TIE2 phosphorylation (pTIE2) as compared to the control group (Figure 1A-B). The summarized data (1B) are presented as the junctional pTIE2 integrated density for individual lanes as well as mean ± SEM; to test for statistical significance (p<0.05) a Student’s t-test (unpaired, two-tailed) was performed.

The enhancement of ANGPT1-TIE2 signaling by COMP-Ang1 in the kidney significantly reduced the terminal urinary albumin to creatinine ratio (UACR, Figure 1C) by 72.9% as well as a reduction in circulating ANGPT2 by 46.2% in contrast to control group (Figure 1D). Treatment ameliorated glomerulosclerosis (Figure 1E) by 36.9%, and reduced interstitial lesions (Figure 1F) by 41.5%. Results are shown from individual animals as well as mean ± SEM; to test for statistical significance (p<0.05) a Student’s t-test (unpaired, two-tailed) was performed. Representative histology images are also shown from an animal with glomerulosclerosis and interstitial lesion scores closest to the group mean (Figure 1E, 1F).

Dose-Responsive Elevation of ANGPT1 using DNA-minicircle and effect on DN progression in db/db mice (Figure 2):

The effect of elevated ANGPT1 was tested using DNA minicircle in db/db mice with uninephrectomy to accelerate DN progression. Three doses of the ANGPT1 minicircle (6, 20 and 60 μg/mouse), or a control
minicircle, were delivered via hydrodynamic injection; doses were selected based on in-house experience with DNA minicircles for other similar proteins (unpublished observation). 24-hr urinary albumin excretion was measured every two weeks for 8 weeks. ANGPT1 minicircle produced a dose-dependent reduction in UAE beginning 4 weeks after administration at the 20 and 60 μg doses. At the end of the study the area under the curve for UAE was calculated and was significantly decreased only in the 60 μg dose group, reduced 56.3% vs. the control group (Figure 2A, results are shown from individual animals and as mean ± SEM; to test for statistical significance (p<0.05) a one-way ANOVA with Dunnett’s multiple comparison test vs. db/db was performed).

Endothelial function was tested by vasodilation of aortic ring response to acetylcholine; a representative dose-response curve for each treatment group is shown in (Supp. Fig. 1). The 60 μg ANGPT1 minicircle treatment exhibited significant restoration of the vasodilation response to acetylcholine treatment compared to the db/db control group (Figure 2B, Mean ± SEM);*p<0.05 vs Control, ^p<0.0001 vs Control as determined by AUC. The summarized data were presented as the mean percent relaxation ± SEM. With the EC50 value for each group shown in the table below the graph.

Finally, significant reductions in glomerulosclerosis were also only observed in 60 μg ANGPT1 minicircle treated group (by 18.1% vs. db/db control group, Figure 2C; results are shown from individual animals and as mean ± SEM; to test for statistical significance (p<0.05) a one-way ANOVA with Dunnett’s multiple comparison test vs. db/db was performed). Representative histology images are also shown from an animal with glomerulosclerosis and interstitial lesion scores closest to the group mean (Figure 2D).

_Circulating Levels of ANGPT1 and ANGPT2 after a single 60 mg dose of ANPGT1 DNA-MC in db/db mice (Figure 3):_
Using the renoprotective dose of ANGPT1 minicircle (60 µg/mouse), a study was performed to define the associated levels of the target protein in plasma. ANGPT1 minicircle was delivered into db/db mice at 8 weeks of age and blood samples were collected every 10 days post transfection. Injection of the minicircle (MC) had no appreciable effect on body weight gain in the animals; at the time of injection body weight (group means) was 35.2 g (Veh) vs. 35.96 g (MC) and at the end of the study (56 days post MC injection), the body weight was 50.87 g (Veh) vs. 49.69 g (MC).

Both circulating ANGPT1 and ANGPT2 were measured. As expected, and despite some variability in measured values, administration of the ANGPT1 minicircle resulted in a relatively sustained elevation in circulating ANGPT1 levels to approximately 85% above pre-dose baseline levels (Figure 3A) although values were only statistically elevated at Day 10 post-dose; to test for statistical significance (p<0.05) a one-way ANOVA with Dunnett’s multiple comparison test vs. Day 0 was performed. The increase in ANGPT1 was biologically relevant as evidenced by a suppression in circulating ANGPT2 levels by roughly 40% (Figure 3B) and indicative of sustained pathway engagement; using the same statistical methodology ANGPT2 values were statistically reduced at each post-dose timepoint. Mathematically, this resulted in a net reduction in the ANGPT2/1 ratio of approximately 75% vs. values in untreated mice where again, using the same statistical methodology the ANGPT2/1 ratio was decreased vs. pre-dose levels at each post-dose timepoint.

Effect of the ANGPT1 non-neutralizing antibody, O010, on DN progression in db/db Unx mice (Figures 4-5):

It was previously reported circulating ANGPT1 levels were significantly increased in cynomolgus monkeys treated with a non-neutralizing anti-ANGPT1 antibody (Zheng et al., 2018). In order to
demonstrate the potential benefit of increasing circulating ANGPT1 levels on the renoprotective efficacy in db/db UNx mice, a study was performed utilizing the same biotherapeutic molecule, termed O010. Treatment with 10mg/kg O010, dosed weekly in db/db UNx mice, significantly increased circulating ANGPT1 protein by 60% but had no effect on systemic ANGPT2; in total the ANGPT2/ANGPT1 ratio was reduced by 45% (Figure 4a-4c; results are shown from individual animals as well as mean ± SEM; to test for statistical significance (p<0.05) a Student’s t-test (unpaired, two-tailed) was performed. However, no statistically significant reduction in UAE was observed either temporally or as an AUC during the course of the study (4d, 4e), including no difference between the IgG and O010 treated db/db mice at the end of the study (week 10 in Figure 4d).

Lack of reduction in UAE was confirmed in a second study testing O010 in db/db mice using a similar study design; in addition, a 60 μg ANGPT1 MC group was included as positive control in the study. Consistent with the first study, 10 mg/kg O010 again failed to reduce urinary albuminuria compared to the IgG isotype control group. This lack of effect was in contrast with that of the ANGPT1 MC that significantly reduced albuminuria as compared to O010 treated mice (Figure 4f; results are shown from individual animals as well as mean ± SEM; to test for statistical significant (p<0.05) a Student’s t-test (unpaired, two-tailed) was performed vs. either IgG1 or O010-treated mice as appropriate).

Finally, 0010 had no beneficial effect on histopathological endpoints including incidence of glomerulosclerosis, interstitial lesion, and podocyte number quantified by IHC of p57 (Figure 5a-c); results are shown from individual animals and as mean ± SEM; to test for statistical significance (p<0.05) a one-way ANOVA with Dunnett’s multiple comparison test vs. the db/db IgG1 group was performed). Representative histology images are shown from an animal with values closest to the group mean.
Effect of the ANGPT1 non-neutralizing antibody, O010, on TIE2 activation and permeability in HUVECs
(Figure 6):

Failure of O010 to reduce circulating ANGPT2 protein levels in db/db UNx mice suggested the antibody may have interfered with some of ANGPT1’s activity. Therefore O010 interference of TIE2 translocation to endothelial adherens junctions was tested, and impact on endothelial cell monolayer permeability, using primary human endothelial cells in vitro. Activated TIE2 receptors translocated to the adherens junctions in HUVEC monolayers following treatment with recombinant ANGPT1, as shown by colocalization of pTIE2 with VE-cadherin by confocal microscopy (Figure 6A) and an increase in quantified junctional pTIE2 levels (Figure 6B). In contrast, when ANGPT1 treatment was performed in the presence of the ANGPT1 antibody, O010, junctional pTIE2 was substantially reduced. The summarized data are presented as the junctional pTie2 integrated density ± SEM from one experiment. Statistical analysis was performed using one-way ANOVA with Dunnett’s multiple comparison test. The functional consequence of ANGPT1-mediated TIE2 activation and translocation to the adherens junctions is enhanced stability of the endothelial monolayer. Thus, in vitro permeability was assessed by creating a stable HUVEC monolayer which could be disrupted by TNFα treatment (Figure 6C). Concurrent treatment of ANGPT1 together with TNFα significantly reduced permeability compared to TNFα alone, supporting the pro-stability function of ANGPT1. While concomitant treatment with the IgG control had no effect, in the presence of the O010 ANGPT1 antibody the protective effect of ANGPT1 is abolished (Figure 6C), suggesting that the interference of the O010 antibody on pTIE2 translocation is critically detrimental to some ANGPT1 function. Data are shown from one of two independent experiments and displayed as mean ± SEM. Statistical analysis was performed using one-way ANOVA with Šídák’s multiple comparisons test, testing for 6 comparisons (Media vs TNF alpha, TNF alpha vs TNF alpha+Angpt1, TNF alpha+Angpt1 vs O010, TNF alpha+Angpt1 vs IgG control, TNF alpha vs O010, and TNF alpha vs IgG Control).* P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Discussion

In the present study several unique strategies to increase ANGPT1 protein levels in the circulation of diabetic-obese mice were tested to assess potential to mitigate progression of diabetic nephropathy. Results confirmed and reproduced data demonstrating that AAV-mediated delivery of COMP-Ang1, a stable and potent variant of ANGPT1, reduces albuminuria and glomerulosclerosis in db/db mice (Lee et al., 2007). Importantly, results also demonstrate that TIE2 activation by COMP-Ang1 reduces the circulating levels of ANGPT2; it has been previously demonstrated that ANGPT1-induced activation of TIE2 increases Akt and FOXO1 signaling, which in turn negatively regulates ANGPT2 gene expression (Daly et al., 2004). Thus, in this series of studies, the use of circulating ANGPT2 levels as an indirect proxy of ANGPT1-TIE2 receptor engagement was validated.

Next, the native form of ANGPT1 was overexpressed in db/db mice using DNA-minicircle and a dose-titration was performed to identify the magnitude of ANGPT1 elevation required for improvement in UACR and glomerulosclerosis in a widely accepted pre-clinical model of diabetic nephropathy. Results demonstrate that an 85% increase in circulating ANGPT1 was sufficient to significantly reduce UACR and the incidence of glomerulosclerosis, and partially restore diabetes-induced endothelial dysfunction. Consistent with the results using COMP-Ang1 to overexpress the protein, native ANGPT1 also reduced ANGPT2 levels by approximately 40%.

Finally, the present study tested a recently described and novel biotherapeutic modality to increase endogenous ANGPT1 protein levels using a non-neutralizing anti-ANGPT1 antibody, referred to as O010, that binds within the coiled-coil domain of ANGPT1 (a site independent of the receptor binding domain) and reduces the clearance, resulting in increased circulating concentrations of ANGPT1. It was previously shown that the O010 antibody does not interfere with ANGPT1 binding to TIE2, nor does it reduce pAKT signaling in a cell line (Zheng et al., 2018). Furthermore, this antibody significantly
increases circulating ANGPT1 levels in healthy cynomolgus monkeys (Zheng et al., 2018) consistent with the targeted mechanism-of-action. The present study also demonstrated an increase in circulating ANGPT1 with O010 in db/db UNx mice, however the molecule failed to reduce renal injury endpoints including no effect on albuminuria or histopathology scores, including the incidence of glomerulosclerosis and interstitial lesions.

Podocytes play a key role in the preservation of normal glomerular structure and function (Pagtalunan et al., 1997) and are the principal source of ANGPT1 release in the kidney where the protein colocalizes with nephrin in the foot process (Satchell et al., 2002). It is well accepted that podocyte loss is associated with the progression of glomerular diseases both in humans and in experimental models of glomerular injury (Matsusaka et al., 2005). Confirming the importance of, and delicate balance in, the ANGPT1-ANGPT2-Tie2 axis in maintaining glomerular integrity, (Davis et al., 1996)demonstrated that inducible ANGPT2 expression in the podocyte itself resulted in significant albuminuria, glomerular endothelial apoptosis, and a loss of nephrin proteins critical for the integrity of the filtration barrier. In this study, animals treated with O010 also failed to protect against podocyte loss, an effect likely contributing to the lack of benefit on albuminuria.

The disconnect in efficacy outcomes between a strategy using ANGPT1 overexpression and treatment with a stabilizing antibody was therefore interrogated. In both studies a 60-85% increase in circulating ANGPT1 was achieved. However, it should be noted that the absolute levels of systemic ANGPT1 in both studies was different; using the ANGPT1 minicircle Cavg protein levels increased to 1.53 ng/mL while with O010 treatment values were slightly less, 1.14 ng/mL. This difference alone may have contributed, at least in part, to the lack of efficacy to reduce renal outcomes with O010.
However, no reduction in circulating ANGPT2 protein levels was observed after treatment with O010 in db/db UNx mice, results suggestive that the ANGPT1:O010 complex may interfere with activation of the TIE2 receptor and consequently, downstream signaling and renoprotection. Of note, in healthy cynomolgus monkeys, O010 also failed to reduce circulating ANGPT2 levels (Zheng et al., 2018) although in that study the impact of the biotherapeutic on disease outcomes was not interrogated. It is plausible that in both cynomolgus monkeys and db/db mice that the lack of ANGPT2-suppression by the molecule may be due to the failure to increase the absolute circulating ANGPT1 levels with O010 treatment to the same extent as observed with the ANGPT1 minicircle.

An alternative, or additional, explanation explored experimentally centered on O010 interference with TIE2 translocation to endothelial adherens junctions; if true, O010-bound ANGPT1 would fail to stabilize the glomerular endothelial cells of the filtration barrier. Indeed, it has been shown that TIE2 signaling is dependent on both receptor and ligand localization (Fukuhara et al., 2008; Saharinen et al., 2008). Promotion of vascular quiescence is regulated by ANGPT1-induced translocation of TIE2 to cell-cell contacts, while angiogenesis is promoted by ECM-anchored ANGPT1 (Fukuhara 2010). Thus, to investigate further, confocal microscopy was used to demonstrate that O010 in fact prevented the translocation of pTIE2 to VE-cadherin+ junctions and blocked the ability of ANGPT1 to stabilize endothelial cell monolayers in vitro. In total, these observations likely more accurately explain the lack of renoprotection with O010, despite an effect of the molecule to increase the systemic levels of the ANGPT1 protein.

This complete body of work is supportive that increasing ANGPT1-TIE2 signaling has the potential to be beneficial in the treatment of diabetic kidney disease. Multiple therapeutic strategies are envisioned including agonizing the TIE2 receptor directly in a localized manner (i.e., at glomerular endothelial cells), precipitating localized ANGPT1 production to promote glomerular endothelial TIE2 activation, or by increasing ANGPT1 concentrations in the circulation in a manner not interfering with TIE2 junctional
translocation. Although the present data, using a novel approach to promote half-life extension of the protein, was negative in terms of efficacy benefit it is undetermined whether the effect is antibody- or epitope-specific, or inherent to all ANGPT1 antibodies employing a similar approach. It is essential that the complex biology around TIE2 signaling and localization be considered in the development of future ANGPT1-elevating therapeutics.

**Authorship Contributions**

*Participated in research design:* Bartlett, Fryer, Grant, Kerr, Sun, Zheng

*Conducted experiments:* Bartlett, Berger, Bigwarfe, Carpenter, Chen, MacDougall, McHugh, Robinson, Sun, Zhang

*Contributed new reagents or analytic tools:* Lamla, Miglietta, Zheng

*Performed data analysis:* Bartlett, Fryer, Kerr, McHugh, Qian, Sun

*Wrote or contributed to the writing of the manuscript:* Bartlett, Fryer, Kerr, Qian, Sun
References

Aschauer DF, Kreuz S, and Rumpel S (2003) Analysis of Transduction Efficiency, Tropism and Axonal Transport of AAV Serotypes 1, 2, 5, 6, 8 and 9 in the Mouse Brain. *PLOS One*.


Footnotes

This work received no external funding.

Financial Disclosure: all authors were employed at Boehringer Ingelheim Pharmaceuticals at the time the research was performed.

No author has an actual or perceived conflict of interest with the contents of this article.
Legends for Figures

**Figure 1.** Transfection of db/db mice with AAV to overexpress COMP-Ang1 (A1 AAV). Overexpression of ANGPT1 A-B) increased renal cortical phosphorylation of TIE2 and C) reduced leakage of albumin into the urine as shown by a decreased UACR at 10 weeks post-AAV. D) ANPGT2 levels were reduced in the presence of ANGPT1-AAV suggesting signaling through the FOXO pathway to downregulate ANPGT2 expression. E-F) By histological assessment, ANGPT1-AAV significantly reduced the incidence of glomerular lesions; reductions in the number of interstitial lesions were not statistically significant. Glomerular lesions stained black by PAM: db/db glomerulus shows expanded matrix throughout the mesangium, and the A1 AVV shows mesangial matrix in ¼ the glomerular area (arrows). Lesions in mice treated with the A1 AVV were fewer and appeared less severe than those observed in db/db mice. Interstitial lesions were stained by H&E: db/db mice present with interstitial cellularity (arrows) while matrix expansion or fibrosis was not observed. The A1 AVV mice showed fewer foci and less cellularity relative to db/db mice. Areas of cellularity were typically associated with tubular dilation.

**Figure 2.** Effect of ANGPT1 elevation using DNA-minicircle on the excretion of albumin, results are shown A) as an area under the curve (AUC) for the duration of the study where 60 µg treatment reduced the UAE significantly in contrast to vehicle control group. DNA-Minicircle overexpression of ANGPT1 also B) significantly improved vascular function in isolated aortic rings. The incidence of glomerulosclerosis was markedly increased in db/db mice relative to db/m controls (C-D). After treatment with ANGPT1 MC, there was a trend for a dose dependent reduction in incidence of glomerulosclerosis when compared with db/db mice. However, only db/db mice treated with 60µg MC reached statistical significance.
**Figure 3.** Increase in circulating ANGPT1, and decrease in circulating ANGPT2 and the ratio between the proteins, at the maximally efficacious dose of ANGPT1 DNA minicircle (60 μg) in a study lasting 56 days in db/db mice. Results were compared to those of an untreated db/db group (open symbol at day 56). The $C_{avg}$ increase in ANGPT1 from baseline was 1.53 ng/mL.

**Figure 4.** Effect of a non-neutralizing antibody to ANGPT1 (O010) in db/db UNX mice on A) Plasma ANGPT1, B) Plasma ANGPT2, C) the ratio of ANGPT2 to ANGPT1. D) Urinary excretion of albumin over 10 weeks, E) Urinary excretion of albumin expressed as an area under the curve, F) Urinary excretion of albumin expressed as an area under the curve as compared to a dose of ANGPT1 DNA minicircle (60µg/mouse) in a second, follow-up, study.

**Figure 5.** Effect of a non-neutralizing antibody to ANGPT1 (O010) in db/db UNX mice, as shown in Figure 4, on histological markers of chronic kidney disease including glomerular lesions (5A) in sections from vehicle (db/m), IgG1 (10 mg/kg, and O010 (10 mg/kg) mice stained by PAM. Glomerulus from Vehicle shows fine mesangial matrix stained black by PAM. IgG1 glomerulus shows expanded matrix throughout the mesangium. Glomerulus from O010 mouse shows slightly less mesangial matrix expansion (arrows). Interstitial lesions (5B) in sections stained by H&E; interstitial disease in all three groups was minimal, mainly showing focal hypercellularity (Arrows). The number of foci with these lesions were higher in IgG1 and O010 groups vs Vehicle. The results for podocyte number (5C) followed a similar trend as observed for glomerulosclerosis and interstitial assessments. Podocyte number was highest in db/m mice; db/db mice that received IgG1 had a significant reduction in average podocyte number that was not improved with O010.
**Figure 6.** Effect of O010 on ANGPT1 function in vitro. Phosphorylated TIE2 receptors within the adherens junctions in HUVECs are shown (A) by colocalization of pTIE2 (green) with VE-cadherin (red) after treatment with ANGPT1 for 30 min, and junctional pTIE2 levels quantified (B). In vitro permeability was assessed (C) using FITC-dextran permeation across a HUVEC monolayer following 24 hrs stimulation with vascular permeability factors (10 ng/mL TNF alpha, 200 ng/mL ANGPT1, and 100 nM O010 or IgG1 control antibody).
Figure 2
Figure 3
Figure 4.
Figure 5
Figure 6
Effect of Novel Biotherapeutic Elevating Angiopoietin 1 on Progression of Diabetic Nephropathy in Diabetic/Obese Mice


Cardiometabolic Diseases Research (CB, PS, MM, VB, SK, HQ, MM, HC, AZ, MC, HR, RF), Biotherapeutic Discovery (CZ, JM), Biotherapeutic Pharmacokinetics (TB, JG), Target Discovery Research (TL)

Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA 06877

S1

Supplemental Figure 1. A representative acetylcholine dose response curve in aortic rings from each treatment group. Mean baseline values following phenylephrine contraction are listed immediately below the figure. Values are shown as mean ± S.E.M. RT, resting tension, PE, phenylephrine.